REPL

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Replimune Group Inc

NASDAQ | REPL

4.13

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$324.71M

Market Cap

-

P/E Ratio

-3.15

EPS

$17.00

52 Week High

$2.68

52 Week Low

HEALTHCARE

Sector

REPL Chart

Recent Chart
Price Action

REPL Technicals

Tags:

REPL Earnings

Yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $0
Cost Of Revenue $3.5M
Costof Goods And Services Sold $3.5M
Operating Income -$262M
Selling General And Administrative $72M
Research And Development $189M
Operating Expenses $262M
Investment Income Net -
Net Interest Income -$7.9M
Interest Income -
Interest Expense $7.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$247M
Income Tax Expense $468K
Interest And Debt Expense -
Net Income From Continuing Operations -$247M
Comprehensive Income Net Of Tax -
Ebit -$265M
Ebitda -$262M
Net Income -$247M

Revenue & Profitability

Earnings Performance

REPL Financials

yearly Balance Sheet (As of Mar 31, 2025)

Field Value (USD)
Total Assets $551M
Total Current Assets $496M
Cash And Cash Equivalents At Carrying Value $111M
Cash And Short Term Investments $111M
Inventory -
Current Net Receivables $3.7M
Total Non Current Assets $55M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $373M
Other Current Assets $8.4M
Other Non Current Assets -
Total Liabilities $135M
Total Current Liabilities $62M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $4M
Total Non Current Liabilities $73M
Capital Lease Obligations $30M
Long Term Debt $46M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $76M
Other Current Liabilities $46M
Other Non Current Liabilities $941K
Total Shareholder Equity $416M
Treasury Stock -
Retained Earnings -$949M
Common Stock $77K
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Mar 31, 2025)

Field Value (USD)
Operating Cashflow -$192M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.5M
Capital Expenditures $6.7M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$24M
Cashflow From Financing $252M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$247M

yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $0
Cost Of Revenue $3.5M
Costof Goods And Services Sold $3.5M
Operating Income -$262M
Selling General And Administrative $72M
Research And Development $189M
Operating Expenses $262M
Investment Income Net -
Net Interest Income -$7.9M
Interest Income -
Interest Expense $7.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$247M
Income Tax Expense $468K
Interest And Debt Expense -
Net Income From Continuing Operations -$247M
Comprehensive Income Net Of Tax -
Ebit -$265M
Ebitda -$262M
Net Income -$247M

REPL News

REPL Profile

Replimune Group Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Replimune Group, Inc. is a pioneering biotechnology company based in Woburn, Massachusetts, focused on the development of oncolytic immunogenic therapies for the treatment of cancer. Leveraging its innovative Immuno-Oncology platform, Replimune aims to harness the power of the immune system to selectively target and destroy tumor cells while promoting robust anti-tumor immune responses. The company is advancing multiple clinical programs that illustrate the effectiveness of its proprietary therapies, positioning itself as a leader in the rapidly evolving field of cancer treatment.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.